Class Action Lawsuits Filed Against PomDoctor and Inovio Pharmaceuticals Over Investor Fraud Allegations

Law firm Bragar Eagel & Squire, P.C. has announced the filing of class action lawsuits against two companies—PomDoctor Ltd. and Inovio Pharmaceuticals Inc.—alleging significant securities fraud and misrepresentation. The legal actions target what investors' counsel characterizes as systematic efforts to deceive shareholders through false claims and misleading disclosures, marking another chapter in the ongoing scrutiny of biotech and micro-cap companies' disclosure practices.

The Allegations Against Both Companies

The two cases present distinct but equally serious allegations of investor deception:

PomDoctor faces accusations of participating in a fraudulent stock promotion scheme involving coordinated social media manipulation and misleading claims about the company's operations and prospects. The lawsuit alleges that the company engaged in coordinated share dumping—a pattern where insiders or promoters sell shares while the stock is artificially inflated through promotional activity. This classic pump-and-dump scheme has become increasingly common in micro-cap and penny stock markets, where regulatory oversight remains challenging.

Inovio Pharmaceuticals ($INO), a clinical-stage biotech company, stands accused of making materially misleading statements regarding two critical areas of investor concern:

• Manufacturing capabilities: The company allegedly misrepresented its ability to produce its therapeutic candidates at scale
• Regulatory prospects: Inovio purportedly made false or misleading statements about the regulatory pathway and likelihood of approval for INO-3107, a key treatment candidate

The regulatory setback proved dramatic. In December 2025, the FDA rejected Inovio's accelerated approval request for INO-3107, a development that clearly contradicted any optimistic public statements about regulatory progress. The market's reaction was swift and severe: $INO stock plunged 24.45% following the FDA decision, wiping out substantial shareholder value and suggesting investors had been operating on materially false premises.

Market Context and Industry Implications

These cases arrive amid heightened regulatory and investor scrutiny of biotech disclosure practices. The sector has faced repeated cycles of overstated clinical trial results, regulatory setbacks, and management credibility crises. Several factors make these allegations particularly significant:

The FDA rejection pattern: Accelerated approval requests represent a critical inflection point for biotech companies. When companies publicly telegraph optimism about such requests and subsequently face rejection, it raises questions about what management knew and when they knew it. The 24.45% stock decline suggests the market had been substantially mispricing the regulatory risk.

Micro-cap vulnerability: Both PomDoctor and Inovio operate in market segments with historically lower analyst coverage and institutional investor participation. This creates an information asymmetry that makes them susceptible to promotional schemes and misrepresentation.

Social media as a vector: The allegations that PomDoctor used coordinated social media claims to drive stock prices reflects a modern evolution of classic securities fraud. Retail investors increasingly source investment theses from social media platforms, creating opportunities for bad actors to exploit information gaps.

The broader biotech sector, already dealing with elevated regulatory uncertainty and clinical trial risks, faces renewed reputational pressure. Companies in early-stage development face investor demands for greater transparency and conservative guidance on regulatory timelines.

Investor Implications and Legal Significance

For shareholders affected by these cases, the class action lawsuits represent potential recovery mechanisms—though the success and ultimate recovery amounts remain uncertain and dependent on case development, litigation strategy, and defendant resources.

Key implications for investors:

• Damages exposure: If successful, these cases could result in substantial damages awards, affecting both companies' financial positions and management's ability to execute business plans. For Inovio in particular, regulatory setbacks combined with litigation costs could materially impair cash runway and clinical development timelines.

• Due diligence lessons: These cases underscore the importance of investor due diligence, particularly for micro-cap and biotech investments where regulatory outcomes carry binary risk characteristics. Statements about manufacturing capabilities and regulatory prospects should be verified against third-party evidence and compared to typical regulatory timelines.

• Governance and credibility: The allegations raise questions about corporate governance, disclosure controls, and management integrity. For Inovio, the rejected accelerated approval request suggests that either (a) the company substantially overestimated its chances, or (b) the company knew its chances were lower but misled investors anyway. Either scenario damages investor confidence.

• Systemic risk in micro-caps: The PomDoctor allegations exemplify risks in less-regulated segments of capital markets, where promotional schemes can gain traction before detection. This may prompt institutional investors to demand better regulatory frameworks for micro-cap securities.

Looking Forward

As these lawsuits proceed, they will likely produce discovery materials that illuminate what these companies' management teams knew about their respective challenges. For Inovio in particular, the legal process may reveal communications about the FDA's likely stance on the accelerated approval request prior to the December 2025 rejection.

Investors holding positions in either company face continued uncertainty. Settlement discussions may begin within months, or cases could extend for years. Bragar Eagel & Squire's invitation for affected investors to contact the firm signals that class definition and case administration mechanics remain in flux.

These cases serve as reminders that spectacular stock declines and regulatory rejections often leave investor losses in their wake—and that securities litigation, while imperfect, remains one of the few accountability mechanisms available to defrauded shareholders in the United States capital markets.